Keith Wafford obtained his undergraduate degree in neurobiology at the University of Sussex, Falmer, UK, and his Ph.D. degree at the University of Cambridge, Cambridge, UK, where his research focused on glutamate and GABA receptors in the invertebrate nervous system. He then moved to the University of Colorado, Denver, Colo, USA, where he carried out postdoctoral research with Drs. Adron Harris and Tom Dunwiddie into the effects of alcohol on GABAA receptors from selectively bred mouse lines using the Xenopus oocyte expression system. In 1990, Dr. Wafford began working at Merck’s Terlings Park Research Centre in the UK. There, he continued his work on GABAA receptors, becoming a Senior Member of the team in molecular pharmacology, contributing much to our understanding of the role of different GABAA receptor subtypes, and generating many useful subtype selective tool compounds and resources for academic researchers investigating GABAA receptor subtypes. Dr. Wafford has formed many collaborations with academic groups in the field of GABAA receptor pharmacology and has published over 120 scientific papers, reviews, and book chapters in the area of neurotransmitters and GABA receptors. Currently, Wafford is a senior scientist at Eli Lilly. He is also presently researching novel mechanisms for the treatment of sleep disorders and associated psychiatric illness.
Biography Updated on 23 November 2011